A Phase 2 interventional study of INCB054707 and Placebo in NonSegmental Vitiligo, sponsored by Incyte Corporation. Completed at 31 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-11.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Vitiligo by Incyte Corporation — 2 open to participants now, 4 under way, 4 of them phase 3. Vitiligo · Incyte Corporation.
Among the 12 studies in Vitiligo by Incyte Corporation, this one is the 8th largest by enrollment, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 5th registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →2 of the 12 studies in Vitiligo by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in Argentina, Austria, Belgium and 11 more countries
Ages 6–11
Incyte Corporation · Sites in United States, Canada
Ages 2–11
By country, each count listing its studies:
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 171 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Median enrollment 215 across the 12 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
1 of the studies in Vitiligo by Incyte Corporation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06804811Phase 3Incyte CorporationA Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Vitiligo by Incyte Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of INCB054707 over a 24-week placebo-controlled double-blind treatment period, followed by a 28-week double-blind extension period in participants with nonsegmental vitiligo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive INCB054707 Dose A for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
Drug: INCB054707
Participants will receive INCB054707 Dose B for 52 weeks (Period 1 + Period 2).
Drug: INCB054707
Participants will receive INCB054707 Dose C for 52 weeks (Period 1 + Period 2).
Drug: INCB054707
Participants will receive placebo for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
Drug: Placebo
INCB054707 will be administered once daily
Also known as: Povorcitinib
Placebo or INCB054707 will be administered once daily
Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24
The T-VASI was calculated based on values from the whole body, which was split into 6 separate and mutually exclusive regions (possible range: 0-100; higher values=worse outcome). The percentage of vitiligo involvement was estimated in hand units (% body surface area \[BSA\]; investigator assessed), based on the participant's hand size. The degree of depigmentation for each body site was determined and estimated to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The T-VASI was derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values of all body sites. Percent change was calculated as (\[post-Baseline value minus the Baseline value\] / Baseline value) x 100.
Time frame: Baseline; Week 24
Percentage of Participants Achieving T-VASI50 at Week 24
T-VASI50 was defined as a 50% or greater reduction from Baseline in T-VASI. The T-VASI was calculated based on values from the whole body, which was split into 6 separate and mutually exclusive body regions (possible range: 0-100; higher values=worse outcome). The percentage of vitiligo involvement was estimated in hand units (% body surface area \[BSA\]; investigator assessed), based on the participant's hand size. The degree of depigmentation for each body site was determined and estimated to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The T-VASI was derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values of all body sites.
Time frame: Baseline; Week 24
Placebo-controlled Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up period.
Time frame: up to Week 24
Extension Period: Number of Participants With Any TEAE
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up period.
Time frame: from Week 25 up to Week 76
| Milestone | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|---|---|---|---|---|
| Started | 43 | 43 | 43 | 42 |
| Completed | 35 | 38 | 32 | 34 |
| Not completed | 8 | 5 | 11 | 8 |
| Withdrew: Adverse event | 1 | 2 | 0 | 3 |
| Withdrew: Lost to follow-up | 3 | 2 | 3 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 6 | 2 |
| Withdrew: Subject terminated by sponsor | 1 | 0 | 0 | 0 |
| Withdrew: Latent tuberculosis; unable to provide proof of treatment | 1 | 0 | 0 | 0 |
| Withdrew: Use of prohibited concomitant medication | 0 | 0 | 1 | 0 |
| Withdrew: Ineligible to be included in the study due to abnormal coagulation profile | 0 | 0 | 0 | 1 |
| Milestone | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|---|---|---|---|---|
| Started | 35 | 37 | 32 | 34 |
| Completed | 33 | 30 | 26 | 28 |
| Not completed | 2 | 7 | 6 | 6 |
| Withdrew: Adverse event | 1 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 | 4 | 3 |
| Withdrew: Non-compliance | 0 | 1 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 | 0 |
| Withdrew: Scheduling conflicts | 0 | 0 | 0 | 1 |
The T-VASI was calculated based on values from the whole body, which was split into 6 separate and mutually exclusive regions (possible range: 0-100; higher values=worse outcome). The percentage of vitiligo involvement was estimated in hand units (% body surface area \[BSA\]; investigator assessed), based on the participant's hand size. The degree of depigmentation for each body site was determined and estimated to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The T-VASI was derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values of all body sites. Percent change was calculated as (\[post-Baseline value minus the Baseline value\] / Baseline value) x 100.
| percent change | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24 | 2.29 ± 4.81 | -19.12 ± 4.56 | -17.78 ± 4.87 | -15.73 ± 4.74 |
T-VASI50 was defined as a 50% or greater reduction from Baseline in T-VASI. The T-VASI was calculated based on values from the whole body, which was split into 6 separate and mutually exclusive body regions (possible range: 0-100; higher values=worse outcome). The percentage of vitiligo involvement was estimated in hand units (% body surface area \[BSA\]; investigator assessed), based on the participant's hand size. The degree of depigmentation for each body site was determined and estimated to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The T-VASI was derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values of all body sites.
| percentage of participants | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving T-VASI50 at Week 24 | 2.3 (0.1 to 12.3) | 9.3 (2.6 to 22.1) | 11.6 (3.9 to 25.1) | 4.8 (0.6 to 16.2) |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up period.
| Participants | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|---|---|---|---|---|
| Placebo-controlled Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 24 | 29 | 30 | 35 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up period.
| Participants | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|---|---|---|---|---|
| Extension Period: Number of Participants With Any TEAE | 27 | 28 | 21 | 31 |
Collected over up to Week 76. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/42 (0%) | 1/42 (2.4%) | 19/42 (45.2%) |
| Povorcitinib 15 mg | 0/43 (0%) | 0/43 (0%) | 22/43 (51.2%) |
| Povorcitinib 45 mg | 0/41 (0%) | 1/41 (2.4%) | 24/41 (58.5%) |
| Povorcitinib 75 mg | 0/114 (0%) | 1/114 (0.9%) | 69/114 (60.5%) |
| Event | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|---|---|---|---|---|
| COVID-19Infections and infestations | 0/42 | 0/43 | 1/41 | 0/114 |
| Acetabulum fractureInjury, poisoning and procedural complications | 1/42 | 0/43 | 0/41 | 0/114 |
| Pelvic fractureInjury, poisoning and procedural complications | 1/42 | 0/43 | 0/41 | 0/114 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/42 | 0/43 | 0/41 | 0/114 |
| Spinal fractureInjury, poisoning and procedural complications | 1/42 | 0/43 | 0/41 | 0/114 |
| Substance-induced psychotic disorderPsychiatric disorders | 0/42 | 0/43 | 0/41 | 1/114 |
| Event | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|---|---|---|---|---|
| COVID-19Infections and infestations | 5/42 | 8/43 | 13/41 | 31/114 |
| AcneSkin and subcutaneous tissue disorders | 0/42 | 0/43 | 3/41 | 22/114 |
| Blood creatine phosphokinase increasedInvestigations | 3/42 | 3/43 | 4/41 | 21/114 |
| HeadacheNervous system disorders | 5/42 | 7/43 | 1/41 | 9/114 |
| Upper respiratory tract infectionInfections and infestations | 1/42 | 3/43 | 6/41 | 6/114 |
| Aspartate aminotransferase increasedInvestigations | 1/42 | 1/43 | 4/41 | 4/114 |
| Urinary tract infectionInfections and infestations | 1/42 | 1/43 | 4/41 | 5/114 |
| NasopharyngitisInfections and infestations | 3/42 | 0/43 | 2/41 | 9/114 |
| Alanine aminotransferase increasedInvestigations | 1/42 | 1/43 | 3/41 | 6/114 |
| DiarrhoeaGastrointestinal disorders | 1/42 | 0/43 | 3/41 | 2/114 |
| Age, Continuous(years) | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg | Total |
|---|---|---|---|---|---|
| Mean | 48.6 ± 12.92 | 45.9 ± 11.56 | 50.2 ± 11.61 | 50.5 ± 11.69 | 48.8 ± 11.99 |
| Sex: Female, Male(Participants) | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg | Total |
|---|---|---|---|---|---|
| Female | 24 | 29 | 21 | 19 | 93 |
| Male | 19 | 14 | 22 | 23 | 78 |
| Race/Ethnicity, Customized(Participants) | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg | Total |
|---|---|---|---|---|---|
| White/Caucasian | 34 | 32 | 38 | 28 | 132 |
| Black/African-American | 2 | 3 | 1 | 3 | 9 |
| Asian | 2 | 4 | 0 | 7 | 13 |
| Mexican American | 1 | 0 | 0 | 0 | 1 |
| African-European | 1 | 0 | 0 | 0 | 1 |
| Middle Eastern | 0 | 1 | 1 | 0 | 2 |
| Columbian | 0 | 0 | 0 | 1 | 1 |
| Captured as Hispanic in Database | 0 | 0 | 0 | 2 | 2 |
| Mixed | 0 | 1 | 0 | 0 | 1 |
| Mexican | 0 | 0 | 1 | 0 | 1 |
| East Indian | 1 | 0 | 0 | 0 | 1 |
| Did Not Identify with Options Provided | 0 | 1 | 0 | 0 | 1 |
| White and Asian-Non-Japanese | 0 | 0 | 1 | 0 | 1 |
| South African | 0 | 1 | 0 | 0 | 1 |
| White/Black | 1 | 0 | 0 | 0 | 1 |
| South American | 0 | 0 | 0 | 1 | 1 |
| Egyptian | 0 | 0 | 1 | 0 | 1 |
| Captured as Hispanic/Latino in Database | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 6 | 11 | 7 | 32 |
| Not Hispanic or Latino | 35 | 36 | 32 | 34 | 137 |
| Not Reported | 0 | 0 | 0 | 1 | 1 |
| Bangladeshi | 0 | 1 | 0 | 0 | 1 |
| Total Vitiligo Area Scoring Index (T-VASI)(scores on a scale) | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg | Total |
|---|---|---|---|---|---|
| Mean | 28.31 ± 21.481 | 27.13 ± 20.085 | 23.64 ± 19.758 | 22.65 ± 14.244 | 25.45 ± 19.094 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from May 2021 to primary completion in May 2022, 12 months.
Results were first posted in Jul 2023, 1 year 1 month after primary completion.
Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Povorcitinib